Association of asthma and hay fever with irregular menstruation

C Svanes, F Gomez Real, T Gislason, C Jansson, R Jögi, E Norman, L Nyström, K Torén, E Omenaas

Background: There is some evidence that asthmatic women are more likely to have abnormal sex hormone levels. A study was undertaken to determine whether asthma and allergy were associated with irregular menstruation in a general population, and the potential role of asthma medication for this association.

Methods: A total of 8588 women (response rate 77%) participated in an 8 year follow up postal questionnaire study of participants of the ECRHS stage 1 in Denmark, Estonia, Iceland, Norway, and Sweden. Only non-pregnant women not taking exogenous sex hormones were included in the analyses (n = 6137).

Results: Irregular menstruation was associated with asthma (OR 1.54 (95% CI 1.11 to 2.13)), asthma symptoms (OR 1.47 (95% CI 1.16 to 1.86)), hay fever (OR 1.29 (95% CI 1.05 to 1.57)), and asthma preceded by hay fever (OR 1.95 (95% CI 1.30 to 2.96)) among women aged 26–42 years. This was also observed in women not taking asthma medication (asthma symptoms: OR 1.44 (95% CI 1.09 to 1.91); hay fever: OR 1.27 (95% CI 1.03 to 1.58); wheeze preceded by hay fever: OR 1.76 (95% CI 1.18 to 2.64)). Irregular menstruation was associated with new onset asthma in younger women (OR 1.58 (95% CI 1.03 to 2.42)) but not in women aged 42–54 years (OR 0.62 (95% CI 0.32 to 1.18)). The results were consistent across centres.

Conclusions: Younger women with asthma and allergy were more likely to have irregular menstruation. This could not be attributed to current use of asthma medication. The association could possibly be explained by common underlying metabolic or developmental factors. The authors hypothesise that insulin resistance may play a role in asthma and allergy.

We investigated whether asthmatic women in a general population more often had irregular menstruation. To the authors’ knowledge, this has not been studied previously. In particular, we wanted to investigate the role of asthma medication. Based on data from a large Northern European population based cohort, this paper presents an analysis of the association of asthma and hay fever with irregular menstruation in women aged 25–54 years.

METHODS

Data collection

The Respiratory Health in Northern Europe (RHINE) is a follow up study of subjects from seven Northern European centres who participated in the European Community Respiratory Health Survey (ECRHS) stage 1, a study that took place in 1990–4. In stage 1 of the ECRHS men and women aged 20–44 years were randomly selected from the population registers from each participating centre. A postal questionnaire was sent to 3000–4000 persons in each centre. The target population for the RHINE study was the responders from Reykjavik in Iceland, Bergen in Norway, Umeå, Uppsala and Göteborg in Sweden, Aarhus in Denmark and Tartu in Estonia (n = 21 802; response rate 83.7%). These (excluding 264 deaths) were sent a postal questionnaire in 1999–2001. Persons not responding to the first mailing were sent two reminders. A total of 16 190 persons answered the questionnaire including 8588 women (response rate 77%) born between 1945 and 1973. The study was approved by the local ethics committees in all the study centres.

The first part of the questionnaire contained 12 questions that were identical with those asked in the ECRHS stage 1 (available at www.ecrhs.org). These items covered respiratory symptoms, asthma symptoms, atopic eczema, hay fever, and with other allergic symptoms (urticaria, rhinitis, conjunctivitis). The second part of the questionnaire was a follow up of the initial postal questionnaire in order to increase the response rate. It was sent to 3000–4000 persons in each centre and contained a total of 36 questions. The second part of the questionnaire was sent to 8588 women (response rate 77%).
symptoms during the last 12 months, current asthma medication, and current hay fever (box 1). “Asthma” was defined as having had asthma attacks during the previous 12 months (Q5) and/or currently taking asthma medication (Q6). The asthma symptoms Q1 to Q6 are grouped as defined in footnotes to the tables. “New” symptoms were defined as having answered “no” to a question in the first survey and “yes” to the same question in the follow up survey. “Persistent” symptoms were defined as having answered “yes” to a question in both surveys.

The second part of the questionnaire included 52 items covering various aspects including hormonal status in women. The women were asked whether their menstrual periods were regular (“Do you have regular menstrual periods?” yes/no/don’t know). Women answering “no” were excluded from the analyses, as were women not responding to the question (n = 288). Pregnant women (n = 260), post-menopausal women (defined as not having had menstruation during the previous 6 months, n = 980), and women currently taking oral contraceptives (n = 1071) or hormonal replacement therapy (n = 655) were also excluded from the analyses. Thus, 6137 non-pregnant women of reproductive age not taking exogeneous sex hormones were left for analysis.

Statistical analysis
Logistic regression analyses were used to assess the effects of irregular menstruation on measures of asthma and hay fever. Separate analyses of women not taking asthma medications were carried out in order to exclude the potential influence of asthma medication on the menstrual cycle. Multiple linear regression analyses of the effects of irregular menstruation on the number of symptoms were performed in order to increase the strength in analyses of new and persistent symptoms which were less common outcome measures. Adjustments were made for age (5 year categories), body mass index (quartiles), smoking habits (never, ex- and current smoking), social class (current type of dwelling), and study centre. A socioeconomic index based on occupation was available for four centres; adjustment for this variable did not influence the results. Potential heterogeneity between centres was studied by meta-analyses.

The biological background for irregular menstruation was considered essentially different in younger and older women, so analyses were stratified by age 43 years, the age when irregular menstruation increased in frequency due to the natural approach of menopause (fig 1).

The analyses were carried out using the statistical software program Stata 7.0 (Stata Corporation, College Station, Texas, USA).

RESULTS
The prevalence of irregular menstruation was 23%, 15% in those aged 25–42 years and 37% among women aged 43–54 years (table 1). Among the younger women, irregular menstruation was more common in those with a higher body mass index and in the shortest and tallest women, while in older women irregular menstruation was associated with more smoking (data not given).

The prevalence of asthma and allergy was higher in women with irregular menstrual periods than in those with regular menstruation in the age group 25–42 years (table 2). Adjusted for smoking habits, body mass index, social class, age and study centre, irregular menstruation was significantly associated with increased risk for asthma, asthma symptoms, and hay fever (table 2). The associations were particularly strong for asthma or wheeze preceded by hay fever. Analysing age at onset of doctor diagnosed asthma involved relatively small numbers and the associations with irregular menstruation did not reach statistical significance, but the size of the estimates appeared to be similar for asthma with onset in childhood (OR 1.33, 95% CI 0.71 to 2.49), in adolescence (OR 1.49, 95% CI 0.86 to 2.59), and in adulthood (OR 1.20, 95% CI 0.78 to 1.84). Excluding 259 women currently using asthma medication, irregular menstruation was still associated with symptoms of asthma and allergy, although there was a tendency towards weaker associations (table 2).

In women aged 43–54 years the prevalence of irregular menstruation increased with age (fig 1), consistent with an increasing number of women entering the perimenopausal transition. In this age group there was no association between irregular menstruation and new onset asthma or symptoms, in contrast to the increase in new onset asthma and higher number of new onset asthma symptoms associated with irregular menstruation among women aged 25–42 years (table 3). These differences between the age groups were significant or of borderline significance (new onset asthma: \( P_{\text{interaction}} = 0.008 \); number of new onset asthma symptoms: \( P_{\text{interaction}} = 0.057 \)). The associations with
persistent asthma and persistent asthma symptoms did not differ between the age groups (table 3).

The results were homogeneous across centres, as shown for the association of asthma with irregular menstruation in fig 2 (heterogeneity = 0.4). There were no significant interactions by body mass index or by current smoking status in the associations of asthma and allergy with irregular menstruation.

DISCUSSION

Women with asthma and allergy more often experienced irregular menstruation. This was observed consistently across centres in non-pregnant women of reproductive age in a population based Northern European cohort. The finding could not be attributed to current asthma medication influencing the menstrual cycle. In women aged 43 years or older, an age when irregular menstruation usually signals the approach of menopause, no association was found for this onset asthma and the general high public awareness of asthma and allergy today argue against such bias.

Asthma and allergy appear to be associated with the pathological conditions underlying irregular menstruation. Our results are in accordance with previous studies reporting that asthmatic women more often have abnormal levels and cyclical patterns of sex steroid hormones, and that women taking asthma medication before the age of 21 years are more often referred for infertility.

Bias related to healthcare seeking behaviour could explain our findings; women with irregular menstruation could see a doctor more often and have their asthma diagnosed more often. However, an association was also found for undiagnosed and untreated asthma symptoms, and there is no general awareness of hormonal factors in women and asthma and allergy. Increased health awareness among women with irregular menstruation—making them more aware of asthma symptoms or vice versa—could also contribute to the findings, but the association with childhood and adolescent onset asthma and the general high public awareness of asthma and allergy today argue against such bias.

A limitation to this study is the crude exposure information. Self-reported irregular menstruation was validated in the Nurses’ Health Study and showed extremely high concordance. The frequency in our study population was similar to that reported in the literature. The causes of self-reported irregular menstruation in an epidemiological population study have not been described to the authors’

Table 1 Characteristics of the 8588 women participating in RHINE

<table>
<thead>
<tr>
<th>Outcome variables</th>
<th>Aarhus (n = 1362)</th>
<th>Reykjavik (n = 1075)</th>
<th>Bergen (n = 1301)</th>
<th>Goteborg (n = 1185)</th>
<th>Umeå (n = 1356)</th>
<th>Uppsala (n = 1351)</th>
<th>Tartu (n = 958)</th>
<th>All (n = 8588)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Irregular menstruation (%)</td>
<td>20</td>
<td>20</td>
<td>21</td>
<td>25</td>
<td>25</td>
<td>28</td>
<td>21</td>
<td>23</td>
</tr>
<tr>
<td>&lt;43 years (%)</td>
<td>11</td>
<td>12</td>
<td>13</td>
<td>14</td>
<td>17</td>
<td>19</td>
<td>20</td>
<td>15</td>
</tr>
<tr>
<td>&gt;43 years (%)</td>
<td>36</td>
<td>33</td>
<td>35</td>
<td>43</td>
<td>37</td>
<td>43</td>
<td>26</td>
<td>37</td>
</tr>
<tr>
<td>Oral contraceptives (%)</td>
<td>14</td>
<td>19</td>
<td>8.6</td>
<td>14</td>
<td>10</td>
<td>16</td>
<td>10</td>
<td>13</td>
</tr>
<tr>
<td>Pregnant (%)</td>
<td>5.6</td>
<td>3.8</td>
<td>3.3</td>
<td>2.9</td>
<td>2.4</td>
<td>2.1</td>
<td>1.8</td>
<td>3.2</td>
</tr>
<tr>
<td>Post-menopausal (%)</td>
<td>8.4</td>
<td>17</td>
<td>17</td>
<td>12</td>
<td>14</td>
<td>11</td>
<td>4.4</td>
<td>12</td>
</tr>
<tr>
<td>Hormone replacement therapy (%)</td>
<td>3.4</td>
<td>18</td>
<td>9.0</td>
<td>8.0</td>
<td>7.6</td>
<td>6.9</td>
<td>1.3</td>
<td>7.6</td>
</tr>
<tr>
<td>Asthma (%)</td>
<td>6.4</td>
<td>8.1</td>
<td>7.4</td>
<td>7.3</td>
<td>11</td>
<td>8.2</td>
<td>1.9</td>
<td>7.3</td>
</tr>
<tr>
<td>Wheeze with shortness of breath and cough (%)</td>
<td>9.1</td>
<td>9.6</td>
<td>15</td>
<td>13</td>
<td>11</td>
<td>7.3</td>
<td>11</td>
<td></td>
</tr>
</tbody>
</table>

Table 2 Asthma and allergy as associated with irregular menstrual periods (using regular menstruation as the referent group) in non-pregnant women aged 25–42 years who were not taking exogenous sex hormones

<table>
<thead>
<tr>
<th>Outcome variables</th>
<th>All women &lt;43 years (n = 4077)</th>
<th>Excluding asthma medication users (n = 3848)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Regular menstruation</td>
<td>Regular menstruation</td>
</tr>
<tr>
<td>Asthma</td>
<td>9.2</td>
<td>6.3</td>
</tr>
<tr>
<td>Asthma attacks</td>
<td>5.0</td>
<td>3.5</td>
</tr>
<tr>
<td>Wheeze</td>
<td>22.8</td>
<td>20.6</td>
</tr>
<tr>
<td>Wheeze with shortness of breath and cough</td>
<td>10.2</td>
<td>7.8</td>
</tr>
<tr>
<td>Night time symptoms†</td>
<td>18.7</td>
<td>12.7</td>
</tr>
<tr>
<td>Three or more asthma symptoms‡</td>
<td>19.6</td>
<td>14.2</td>
</tr>
<tr>
<td>Hay fever or nasal allergy</td>
<td>28.8</td>
<td>23.6</td>
</tr>
<tr>
<td>Asthma and hay fever</td>
<td>6.1</td>
<td>4.1</td>
</tr>
<tr>
<td>Asthma preceded by hay fever</td>
<td>6.0</td>
<td>3.0</td>
</tr>
<tr>
<td>Wheeze preceded by hay fever</td>
<td>10.1</td>
<td>5.6</td>
</tr>
</tbody>
</table>

*From logistic regression models with adjustment for smoking habits, type of dwelling, BMI, age, and centre.
†Waking with tightness in chest (Q2) or waking with shortness of breath (Q3).
‡Symptoms Q1–Q6: Wheeze, wheeze with shortness of breath, wheeze without cold, waking with tightness in chest, waking with shortness of breath, waking with cough, asthma attacks, current asthma medication.
knowledge, but polycystic ovary syndrome accounts for 73–90% of oligomenorrhea or amenorrhea cases in women referred to a specialist.17–19 In the Nurses’ Health Study self-reported irregular menstruation was related to cardiovascular disease20 and to type 2 diabetes,21 both suggesting a role for polycystic ovary syndrome.

Lactation is a non-pathological cause of irregular menstruation about which little is known. Based on the number of pregnant women in the study population and the duration of breast feeding common in the study area, we estimate that 15–20% of cases of irregular menstruation among the younger women may be related to lactation. Asthma and allergy do not seem to be more common among lactating women.22 23 Thus, the true association with irregular menstruation due to pathological conditions may be stronger than that presented in this analysis, due to attenuation by inclusion of lactating women without increased risk.

There are three possible theoretical reasons for a valid association of irregular menstruation and asthma: (1) asthma or asthma medication may cause disturbances in the menstrual cycle, (2) irregular menstruation or its treatment may cause asthma, and (3) common aetiiological factors may cause both irregular menstruation and asthma/ allergy. Considering the first, oral steroids used in the treatment of asthma probably do influence the cyclic variation and levels of sex hormones.5 Kos-Kudla et al found that inhaled steroids had an effect on the levels and circadian variation of sex steroid hormones, but an effect was also found in asthmatic women not taking asthma medication. Only 259 of the women in our study used any asthma medication and, when these were excluded, asthma symptoms and hay fever were still significantly related to irregular menstruation. Thus, adverse effects of current asthma medication cannot explain our findings. The stress of asthma might be suspected to cause disturbances in the menstrual cycle. However, asthma of such severity is usually treated medically in Northern Europe and current stress could not explain the associations with childhood and adolescent asthma.

Secondly, the sex hormone imbalance underlying irregular menstruation or its treatment might cause asthma and allergy. The literature gives several pieces of evidence that female sex hormones do influence physiological processes involved in asthma and allergy.24 Furthermore, women with irregular menstruation may be treated with hormonal cures in order to induce pregnancy or with oral contraceptives due to hyperandrogenism or dysmenorrhea. Asthma and allergy could be side effects of exogenous sex hormones, but women taking oral contraceptives at the time of the survey were excluded from the analyses. These explanations seem unlikely as irregular menstruation was associated with asthma starting in childhood as well as with asthma starting after puberty.

Finally, the association of irregular menstruation with asthma and allergy could be explained by common aetiological factors. Developmental disadvantage in early life such as poor intrauterine conditions is related both to an increased risk for asthma25 and to hormonal imbalance.26–28 Common underlying metabolic disease is another possible explanation. Irregular menstruation may be caused by polycystic ovary syndrome, a manifestation of metabolic syndrome that can be treated with insulin sensitising drugs such as metformin.29 Metabolic syndrome or “syndrome X” is characterised by insulin resistance and dyslipidaemia, and is a causal factor of major importance for cardiovascular disease and several other diseases of the western civilisation.30 There are no studies of metabolic syndrome and asthma or allergy, but several studies have reported associations between lung function and insulin resistance.31–33 The authors hypothesise that insulin resistance may have a role in the causation of asthma and allergy as well as in polycystic ovary syndrome, thereby explaining the association of asthma and hay fever with irregular menstruation. This hypothesis could possibly help to clarify the complex and contradictory findings concerning asthma and other aspects of hormonal status in women. It could also explain the association of asthma with body mass index34–36 and the complex associations of asthma with dietary factors.37

| Table 3 | Associations of irregular menstruation with new and persistent asthma and asthma symptoms in 4077 women aged 25–42 years and 2060 women aged 43–54 years |
|-----------------|-----------------|-----------------|
| Asthma | Number of asthma symptoms* |
| OR (95% CI)† | [Coefficient]‡ |
| New onset | | |
| Age 25–42 years | 1.58 (1.03 to 2.42) | 0.10 (0.00–0.19) |
| Age 43–54 years | 0.62 (0.32 to 1.18) | -0.04 (–0.16–0.08) |
| Persistent | | |
| Age 25–42 years | 1.43 (0.89 to 2.30) | 0.15 (0.06–0.25) |
| Age 43–54 years | 1.41 (0.79 to 2.51) | 0.11 (0.02–0.23) |

*Symptoms Q1–Q6: Wheeze, wheeze with shortness of breath, wheeze without cold, waking with tightness in chest, waking with shortness of breath, waking with cough, asthma attacks, current asthma medication.
†From logistic regression models with adjustment for smoking habits, type of dwelling, BMI, age, and centre.
‡From multiple linear regression model with adjustment for smoking habits, type of dwelling, BMI, age, and centre.

Figure 2 Odds ratios for the association of irregular menstruation with asthma (current asthma medication and/or asthma attacks in previous 12 months) by centre, including 4077 non-pregnant women aged 25–43 years who were not taking exogenous sex hormones. Adjustment within centre for body mass index, smoking, social class, and age. For each centre horizontal lines indicate 95% CI. For combined odds ratio the diamond indicates 95% CI from the model with the centre as random effect. The size of each square is proportional to the sample size.
A study of women with endometriosis showed a higher prevalence of asthma and allergy than that described for the general population, and leukotriene antagonists intended for asthma treatment have been used in the treatment of endometriosis. Endometriosis and asthma/allergy may therefore have common inflammatory features which could explain some of the association between irregular menstruation and asthma/allergy. However, the disease accounts for a relatively small number of women with irregular menstruation. Irregular menstrual periods may be due to poor general health, but this is not very common and severely stressed or ill women are less likely to have participated twice in our investigation. In any case, there may be subgroups of women with irregular menstruation with a strongly increased risk for asthma and allergy, and this should be investigated further.

In conclusion, this study is the first to show that asthma and allergy are related to irregular menstrual periods. This was observed in a general population, was consistent with two reports of abnormal sex hormone levels in women with asthma. These findings raise the question whether asthma/allergy with irregular menstruation may give a clue to further understanding the physiology of asthma. We believe that the association may be explained by common aetiological factors, and speculate that insulin resistance might have a role in the multifactorial aetiology of asthma and allergy, or that a developmental disadvantage may explain the association of asthma and allergy with irregular menstruation.

ACKNOWLEDGEMENTS
The authors acknowledge the helpful contributions made by the following scientists in the RHINE study group: T Blöndal, U Sjöström, M Cackovic, E Heuf, G Omenaas, E Real, S Schatz, M Solomon, C Svanes, G Wieslander. The authors acknowledge the helpful contributions made by the following scientists in the RHINE study group: Olofsson, S Lindh, R Banda, C Stenersen, J Vikander, J Mårtensson, I Nystrom, M Sitges-Serra, E Norrman, P Andreasen, K Lindahl, L Berndtsson, B Sfringer, J Fuchs, M Steffensen, L Holst, B N Lærum, D Norbaeck, E Norrman, A-C Olin, E Rydén, U Spetz-Nystrom, C K Stenudd, M Söderberg, J Talvik, A Tunsaeter, L Wenzel, G Wieslander.

Authors’ affiliations
C Svanes, F G Real, Institute of Medicine, University of Bergen, 5021 Bergen, Norway
C Svanes, E Omenaas, Department of Thoracic Medicine, Haukeland University Hospital, 5021 Bergen, Norway
F G Real, Department of Gynaecology and Obstetrics, Haukeland University Hospital, 5021 Bergen, Norway
T Gislason, Department of Pulmonary Medicine, Landspitali University Hospital, 105 Reykjavik, Iceland
C Jansson, Department of Medical Sciences: Respiratory Medicine and Allergology, Uppsala University, 77185 Uppsala, Sweden
R Jogi, Foundation Tartu University Clinics, Lung Clinic, 51014 Tartu, Estonia
E Norrman, Department of Pulmonary Medicine and Allergology, Umeå University, 90185 Umeå, Sweden
L Nystrom, Department of Public Health, Clinical Medicine, Epidemiology, Umeå University, 90185 Umeå, Sweden
K Torén, Department of Occupational and Environmental Medicine, Sahlgrenska University Hospital, 41266 Göteborg, Sweden

The study was supported financially by the Icelandic Research Council, the Swedish Heart and Lung Foundation, the Vårdal Foundation for Health Care Science and Allergy Research, the Swedish Association Against Asthma and Allergy, the Norwegian Research Council project 135773/330, the Norwegian Asthma and Allergy Association, the Danish Lung Association and the Estonian Science Foundation grant no 4350.

Competing interests: Cecilie Svanes has received 5000 Nkr (approximately 600 Euro) from MSD in January 2004 for giving a speech on asthma in women and an independent educational grant of 100 000 Nkr (approximately 11 800 Euro) from GlaxoSmithKline in 2002 for the project “Asthma in women”.

REFERENCES
Intrapleural streptokinase does not improve outcomes in empyema

Intrapleural fibrinolytic agents have been advocated in the management of pleural infection in many respiratory society guidelines. However, the evidence base for this recommendation stems from case series and small trials which do not have adequate statistical power.

The MIST1 study was a double blind, randomised, controlled trial with 454 patients enrolled in 52 centres in the UK. The inclusion criteria were the presence of macroscopically purulent pleural fluid, positive pleural fluid bacterial culture or gram stain, or a pleural fluid pH <7.2. All patients received IV antibiotics and underwent chest tube insertion. Patients enrolled received either 250 000 IU streptokinase administered through the chest tube every 12 hours (maximum 6 doses) or matched placebo. The primary outcome measure used was the number of patients who died or required surgical drainage at 3 months. Secondary end points included death or surgery at 12 months, duration of hospital stay, the severity of residual chest radiographic changes, and dynamic lung volumes 3 months after randomisation. Also noted were levels of antistreptokinase antibody from baseline to 3 months and any bleeding after surgical drainage of the empyema.

Statistical analysis was performed on 430 subjects (the 24 excluded either died, underwent surgery, or withdrew consent before receiving the drug). Results evaluated after 3 and 12 months revealed, rather unexpectedly, that there was no improvement in outcomes with streptokinase. In fact, there was an increase in adverse events—notably chest pain and allergic reactions. Also, the elevated antibody response raises concerns for receiving streptokinase in any future thrombotic events. The authors therefore conclude that intrapleural streptokinase should generally be avoided in pleural infections.

M Menon
Specialist Registrar in Respiratory Medicine, Princess Alexandra Hospital, Harlow, Essex, UK; mkmenon@doctors.org.uk

Lung Alert

Intrapleural streptokinase does not improve outcomes in empyema

Intrapleural fibrinolytic agents have been advocated in the management of pleural infection in many respiratory society guidelines. However, the evidence base for this recommendation stems from case series and small trials which do not have adequate statistical power.

The MIST1 study was a double blind, randomised, controlled trial with 454 patients enrolled in 52 centres in the UK. The inclusion criteria were the presence of macroscopically purulent pleural fluid, positive pleural fluid bacterial culture or gram stain, or a pleural fluid pH <7.2. All patients received IV antibiotics and underwent chest tube insertion. Patients enrolled received either 250 000 IU streptokinase administered through the chest tube every 12 hours (maximum 6 doses) or matched placebo. The primary outcome measure used was the number of patients who died or required surgical drainage at 3 months. Secondary end points included death or surgery at 12 months, duration of hospital stay, the severity of residual chest radiographic changes, and dynamic lung volumes 3 months after randomisation. Also noted were levels of antistreptokinase antibody from baseline to 3 months and any bleeding after surgical drainage of the empyema.

Statistical analysis was performed on 430 subjects (the 24 excluded either died, underwent surgery, or withdrew consent before receiving the drug). Results evaluated after 3 and 12 months revealed, rather unexpectedly, that there was no improvement in outcomes with streptokinase. In fact, there was an increase in adverse events—notably chest pain and allergic reactions. Also, the elevated antibody response raises concerns for receiving streptokinase in any future thrombotic events. The authors therefore conclude that intrapleural streptokinase should generally be avoided in pleural infections.

M Menon
Specialist Registrar in Respiratory Medicine, Princess Alexandra Hospital, Harlow, Essex, UK; mkmenon@doctors.org.uk